Back to Search
Start Over
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
- Source :
- Therapeutic Advances in Neurological Disorders, Vol 13 (2020), Therapeutic Advances in Neurological Disorders
- Publication Year :
- 2020
- Publisher :
- SAGE Publications Ltd, 2020.
-
Abstract
- Background: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. Methods: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan–Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. Results: Time span under observation in the Italian MS Registry was 1–137 (median 80.3) months. In the total Italian patient population ( n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5–39.5) months. Conclusion: CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.
- Subjects :
- Pediatrics
medicine.medical_specialty
effectiveness
cladribine tablets
registry
multiple sclerosis
lcsh:RC346-429
long-term data
03 medical and health sciences
0302 clinical medicine
secondary progressive MS
medicine
In patient
030212 general & internal medicine
Cladribine
clinically isolated syndrome
real-world data
real-world evidence
relapsing-remitting MS
lcsh:Neurology. Diseases of the nervous system
Original Research
Pharmacology
Clinically isolated syndrome
business.industry
Multiple sclerosis
medicine.disease
Term (time)
Neurology
Long term data
Neurology (clinical)
Previously treated
business
Real world data
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Neurological Disorders, Vol 13 (2020), Therapeutic Advances in Neurological Disorders
- Accession number :
- edsair.doi.dedup.....cf9d78f319f1f857101aee2a219d69b9